AGER and COVID-19: Previous findings that EGCG dose-dependently downregulated RAGE and increased a soluble RAGE competing with RAGE in patients with type II diabetes [183] indicate that EGCG may decrease the mortality of COVID-19 patients with diabetes comorbidity.